PSI ToxSIG Webinar: Beyond the looking glass - Interpreting animal welfare & behaviour by monitoring & assessing mice activity data
Analysing continuously collected locomotive activity data to interpret mice welfare and behaviour.
For the last event of 2012, Simon Kirby and Kayode Ogungbenro joined us to present their work on modelling in drug development.
CHAIR: Stephen Pyke, GSK
Speaker: Kayode Ogungbenro, Centre for Applied Pharmacokinetic Research, The University of Manchester
Application of optimal design methodologies in clinical pharmacology experiments
Co-authors: Aristides Dokoumetzidis and Leon Aarons;
Pharmaceutical Statistics, Volume 8, Issue 3, Pages 239–252, July/September 2009
Abstract | Paper+ | Slides
Speaker: Simon Kirby, Pfizer
Discounting phase 2 results when planning phase 3 clinical trials
Co-authors: J. Burke, C. Chuang-Stein and C. Sin;
Pharmaceutical Statistics, Volume 11, Issue 5, Pages 373–385, September/October 2012
Abstract | Paper+ | Slides
Analysing continuously collected locomotive activity data to interpret mice welfare and behaviour.
Our next journal club features two papers on the topic of Survival Analysis. For each of these published papers there will be a 20 minute presentation by author followed by a 10 minute discussion.
The field of data visualization is the intersection of data journalism, statistics, graphic design, computer science, neuroscience, and cognitive psychology. We will focus on the latter two fields of data visualization as it relates to data visualization: neuroscience and cognitive psychology.
Hear about potential strategies to handle non-proportional hazards and delayed treatment effects from experts in the field.
As a statistician in the Biostatistics and Programming Department, you will be responsible for the methodological and statistical aspects of projects in early clinical development in order to optimize the early development plan and ensure its coherence.
By joining our company, in this role you will apply your skills and experience in support of developing scientifically based arguments aiming to provide fair accessibility to our company’s drugs and vaccines making a real difference in patient’s lives.
As a Director of Statistics, you will be accountable for guiding statisticians in their work, performing senior review of documentation and output deliveries, providing oversight and advising on best practices approach to statistics for clinical trials.